CAS Number202825-46-5
Synonyms(S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide; N-{4-[(3-Fluorobenzyl)oxy]benzyl}-L-alaninamide methanesulfonate (1:1); Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate (1:1); (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide,methanesulfonic acid; PNU-151774E,NW-1015; Safinamide mesylate; (S)-2-(4-(3-fluorobenzyloxy)benzylamino)propanamide,methanesulfonate; (S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propanamide; FCE-28073(R-isomer),PNU-151774E,NW-1015
Molecular FormulaC17H19O2N2F1
Molecular Weight302.35
Purity96+%
Boiling Point476.7ºC at 760 mmHg
Melting Point210° (dec)
EINECS0
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 202825-46-5 |
| Catalog No. | 2A-0100998 |
| Chinese Name | 沙芬酰胺甲磺酸盐 |
| Synonyms | (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide; N-{4-[(3-Fluorobenzyl)oxy]benzyl}-L-alaninamide methanesulfonate (1:1); Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate (1:1); (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide,methanesulfonic acid; PNU-151774E,NW-1015; Safinamide mesylate; (S)-2-(4-(3-fluorobenzyloxy)benzylamino)propanamide,methanesulfonate; (S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propanamide; FCE-28073(R-isomer),PNU-151774E,NW-1015 |
| Molecular Formula | C17H19O2N2F1 |
| Molecular Weight | 302.35 |
| Purity | 96+ |
| Boiling Point | 476.7ºC at 760 mmHg |
| Melting Point | 210° (dec) |
| Storage Condition | 2~8℃, dry, sealed |
| Application | Safinamide mesylate is a potent, selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC50=0.098 µM) and less selective for MAO-A (IC50=580 µM). Safinamide mesylate also blocks sodium chann |
| EINECS | 0 |
| HTC | 2924299090 |
| UN(IATA) | 0 |
| MDL Number | MFCD00897036 |
| SMILES | CC(NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O.CS(=O)(=O)O |
| InChI | InChI=1S/C17H19FN2O2.CH4O3S/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14;1-5(2,3)4/h2-9,12,20H,10-11H2,1H3,(H2,19,21);1H3,(H,2,3,4)/t12-;/m1./s1 |
| InChI Key | YKOCHIUQOBQIAC-YDALLXLXSA-N |
| Hazard Symbols | transportation |
| MSDS | msds/100998_1_202825_46_5.pdf |
| Bioactivity | Safinamide mesylate mesylate (FCE 26743 mesylate; EMD 1195686 mesylate) is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM)[1]. Safinamide mesylate also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide mesylate has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3]. Related Catalog Research Areas >> Cardiovascular Disease Signaling Pathways >> Neuronal Signaling >> Monoamine Oxidase Research Areas >> Neurological Disease Target MAO-B:98 nM (IC50) MAO-A:580 nM (IC50) In Vitro Safinamide mesylate (1-300 µM) reduces the amplitude of the peak sodium currents in a concentration-dependent manner. When currents are stimulated to a Vtest of +10 mV from a Vh of -110 mV, the IC50 value was 262 µM. When the holding potential is depolarized to -53 mV, the inhibitory effect of Safinamide mesylate with a lower IC50 value (8 µM) in rat cortical neurons[1]. In Vivo Safinamide mesylate (intraperitoneal injection; 90 mg/kg; once daily; 14 days) treatment prior to MCAO significantly ameliorates MCAO-caused cerebral infarction volume, neurological deficit, disruption of the brain-blood barrier (BBB), and impairs expression of tight junction protein occludin and ZO-1 in mice[3]. Safinamide mesylate (intraperitoneal injection; 5 mg/kg, 15 mg/kg and 30 mg/kg) dose dependently inhibits the veratridine-induced GABA release and Glu release in vivo. At the dose 30 mg/kg, Safinamide mesylate prevents the effect of veratridine both on Glu (treatment F1,8=1.31; time×treatment interaction F8,64=2.4) and GABA (treatment F1,8=4.04; time F8,64=3.76, time×treatment interaction F8,64=2.83) release. Safinamide mesylate causes a slight, albeit not significant, reduction of veratridine-stimulated Glu release at 0.5 mg/kg and full inhibition at 5 and 15 mg/kg in rat[3]. References [1]. Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50(20), 4909-4916. [2]. C Caccia, et al.Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006 Oct 10;67(7 Suppl 2):S18-23. [3]. Michele Morari, et al. Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.J Pharmacol Exp Ther. 2018 Feb;364(2):198-206. Chemical & Physical Properties Boiling Point 476.7ºC at 760 mmHg Melting Point 210° (dec) Molecular Formula C18H23FN2O5S Molecular Weight 398.449 Flash Point 242.1ºC Exact Mass 398.131165 PSA 127.10000 LogP 4.04410 Vapour Pressure 2.98E-09mmHg at 25°C InChIKey YKOCHIUQOBQIAC-YDALLXLXSA-N SMILES CC(NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O.CS(=O)(=O)O |
| Use of | Properties Name Safinamide mesylate salt Synonym More Synonyms Safinamide Mesylate Biological Activity Related Catalog Research Areas >> Cardiovascular Disease Signaling Pathways >> Neuronal Signaling >> Monoamine Oxidase Research Areas >> Neurological Disease MAO-B:98 nM (IC50) MAO-A:580 nM (IC50) References [2]. C Caccia, et al.Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006 Oct 10;67(7 Suppl 2):S18-23. [3]. Michele Morari, et al. Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.J Pharmacol Exp Ther. 2018 Feb;364(2):198-206. Chemical & Physical Properties Molecular Formula C18H23FN2O5S Exact Mass 398.131165 PSA 127.10000 LogP 4.04410 InChIKey YKOCHIUQOBQIAC-YDALLXLXSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 30.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Dangerous Regulations for land transport: 2811 International Dangerous Regulations for sea transport: 2811 International Dangerous Regulations for air transport: 2811 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: TOXIC SOLID, ORGANIC, N.O.S. (Safinamide mesylate salt) IMDG Code: TOXIC SOLID, ORGANIC, N.O.S. (Safinamide mesylate salt) International air transport hazard regulations: Toxic solid, organic, n.o.s. (Safinamide mesylate salt) 14.3 Transport hazard categories European Land Transport Danger Regulations: 6.1 International Maritime Transport Danger Regulations: 6.1 International Air Transport Danger Regulations: 6.1 14.4 Package group European Land Transport Danger Regulations: III International Maritime Transport Danger Regulations: III International Air Transport Danger Regulations: III 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Pharmaceutical Intermediates | ||
|---|---|---|
| (S)-2-((2,4-DINITROPHENYL)AMINO)PROPANOIC ACID | 1655-52-3 | 2A-0100988 |
| (S)-2-((2-(TRIFLUOROMETHYL)PHENOXY)METHYL)OXIRANE | 134598-04-2 | 2A-0100989 |
| (S)-2-((2-OXO-3-(4-(3-OXOMORPHOLINO)PHENYL)OXAZOLIDIN-5-YL)METHYL)ISOINDOLINE-1,3-DIONE | 446292-08-6 | 2A-0100991 |
| (S)-2-((2S,3R)-2-AMINO-3-HYDROXYBUTANAMIDO)-3-PHENYLPROPANOIC ACID | 16875-27-7 | 2A-0100992 |
| (S)-2-((2S,3S)-2-(((BENZYLOXY)CARBONYL)AMINO)-3-METHYLPENTANAMIDO)-3-PHENYLPROPANOIC ACID | 13254-07-4 | 2A-0100993 |
| (S)-2-((DIMETHYLAMINO)METHYL)-3-(3-METHOXYPHENYL)-3-OXOPROPANAL | 1212197-62-0 | 2A-0101002 |
| (S)-2-((ISOPROPOXYCARBONYL)AMINO)-3-METHYLBUTANOIC ACID | 140923-27-9 | 2A-0101003 |
| (S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOIC ACID | 74761-42-5 | 2A-0101005 |
| (S)-2-((R)-2-CARBOXY-3-PHENYLPROPANAMIDO)-4-METHYLPENTANOIC ACID | 102601-55-8 | 2A-0101006 |
| (S)-2-((S)-1-((BENZYLOXY)CARBONYL)PYRROLIDINE-2-CARBOXAMIDO)-3-PHENYLPROPANOIC ACID | 17350-17-3 | 2A-0101007 |
| Browse all Pharmaceutical Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS